Medical Device MFG Business Raising Funds In Hyderabad

About Business

The device uses a multi-wave system combined with an advanced skin-sensor glucometer to measure blood glucose non-invasively. This technology eliminates the need for blood samples, removing pain, needle pricks, infection risks, and any possibility of bio-contamination.

Clientele type

The company serves both B2B and B2C markets and also caters to government institutions. Its customer base includes individuals with diabetes who require frequent glucose monitoring, healthcare establishments such as hospitals, clinics, and diagnostic centers, as well as medical professionals like doctors, nurses, and diabetes educators. Additionally, caregivers and family members of diabetic patients are key users, valuing convenience and improved patient comfort.

Premises

LEASED

Lease per month (in INR): 20.00 K

Security Deposit (in INR): 2.00 L

Carpet Area: 2,000 sq ft

The premise lease is renewed every year.

Asking Price Includes

1. Equity Investment Option – 15% Stake
For an investment of INR 10 crore (approximately USD 1.2 million), the promoter will issue 15% equity in the company to the investor.
---
2. Full Acquisition Option – 100% Equity + Patent License (India)
For a one-time payment of INR 20 crore (approximately USD 2.5 million), the investor will receive:

- 100% ownership of the company
- Exclusive rights to use the Indian patent for the full patent term of 20 years
- Continued involvement and technical support from the inventors in R&D and product development until the product is launched

The global patent rights (PCT) will remain with the patent holders, and international licensing rights (outside India) can be negotiated separately on a royalty basis.
--
3. Merger / Strategic Integration Option
The investor may merge their company with the existing entity by:

- Paying INR 10 crore (approximately USD 1.2 million) to the founders
- Issuing additional shares worth INR 10 crore (approximately USD 1.25 million) in the investor’s company or the newly merged entity

In return, the investor will receive:

- Exclusive rights to manufacture and sell the product in India for the complete patent period of 20 years
- Access to the patented technology through an Indian license

The global patent rights and PCT will stay with the patent owners. International distribution or licensing rights can be discussed separately on mutually agreeable royalty terms.

Asking Price

INR 20.00 Cr

Minimum ticket size

INR 10.00 Cr

Reason

Raising capital to onboard strategic partners and investors who can support faster development, testing, regulatory approvals, and successful commercialization of the product.

More Details

A skilled team of researchers, engineers, and healthcare professionals has developed solutions designed to simplify life for diabetic patients by enabling pain-free testing and offering multiple assessments at no cost.

The team includes a CTO, two software engineers, one hardware engineer, two clinical research assistants, one mechanical engineer, one product development engineer, and two office staff members. Together, they bring over 25 years of combined experience in advanced technologies such as microscopic digital image analysis.

Their core R&D efforts focus on creating a non-invasive glucometer, hemoglobin meter, HbA1c meter, and exploring alternative imaging technologies for X-ray applications.